Verdad Advisers’s Arcellx ACLX Stock Holding History

Verdad Advisers’s Portfolio ACLX Stock Details ACLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$332K	Buy	+2,893	New	+$255K	0.37%	95

Other funds holding ACLX

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity International

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Verdad Advisers's ACLX Position: Q1 2026 in Review

Verdad Advisers opened a new position in Arcellx (ACLX) in Q1 2026: 2,893 shares worth $332K. The stake represents 0.37% of the portfolio and ranks #95 among its holdings.

239 funds tracked by Wall St. Rank hold ACLX as of Q1 2026.

Verdad Advisers held 2,893 shares of Arcellx worth $332K as of Q1 2026.
Arcellx was a new Verdad Advisers position in Q1 2026.
Arcellx made up 0.37% of Verdad Advisers's portfolio in Q1 2026, its #95 holding.
239 funds tracked by Wall St. Rank held Arcellx as of Q1 2026.

Based on Verdad Advisers's 13F filing for Q1 2026, filed 15 May 2026.